Daniel Cohen

TL;DR: The feasibility of noninvasively imaging the PD-L1 status of tumors by small-animal PET studies is demonstrated by 18F-BMS-986192, which bound to tumor tissues as a function of PD- L1 expression determined by immunohistochemistry.

TL;DR: Alanine-scanning mutagenesis confirmed the calculated binding energies of these β strand interactions, indicating that these nonloop residues can expand the available binding footprint.

TL;DR: The identification of an energetic epitope is reported by determining the interfacial hot-spot that dominates the binding affinity for an anti-interleukin-23 (anti-IL-23) antibody by using the complementary approaches of hydrogen/deuterium exchange mass spectrometry (HDX-MS), fast photochemical oxidation of proteins (FPOP), alanine shave mutagenesis, and binding analytics.

TL;DR: Results indicate specific biodistribution to the spleen, which can be blocked by co-administration of excess nivolumab, and distribution to other organs is consistent with elimination pathways of antibodies, with primary clearance through the liver.

TL;DR: The structural changes induced upon binding were studied by probing the solution conformations of full length EGFR alone and bound to a cognate adnectin through hydrogen/deuterium exchange mass spectrometry (HDX MS) and the effects of binding in solution were identified and compared with the structure of a bound complex determined by X-ray crystallography.